Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Fineline Cube Dec 10, 2025
Company Deals

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Fineline Cube Dec 10, 2025
Company Deals

Shandong Boan Licenses US Rights for Denosumab Biosimilars to Nanjing Kingfriend in $75 Million Deal

Fineline Cube Dec 10, 2025
Company Deals

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development

Fineline Cube Dec 10, 2025
Company Deals

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Fineline Cube Dec 10, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

Fineline Cube Dec 11, 2025
Company Drug

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

Fineline Cube Dec 10, 2025
Company Drug

Huadong Medicine’s Biosimilar Victoza (Liraglutide) Accepted for NMPA Review

Fineline Cube Jul 14, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...

Company R&D

CorrectSequence Therapeutics’ tBE Tech Wins USPTO Patent for Gene Editing

Fineline Cube Jul 14, 2022

Shanghai-based gene editing firm CorrectSequence Therapeutics announced it has received a patent from the United...

Company Drug

Zai Lab’s Efgartigimod NDA Accepted by NMPA for Myasthenia Gravis

Fineline Cube Jul 14, 2022

Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that the National Medical Products Administration (NMPA)...

Company Deals

Overland ADCT BioPharma Doses First Patient in Zynlonta’s Phase III LOTIS-5 Study for DLBCL

Fineline Cube Jul 14, 2022

Overland ADCT BioPharma (CY) Ltd, a joint venture between China’s Overland Pharmaceuticals and Switzerland’s ADC...

Company Deals

Triastek Partners with Eli Lilly to Explore 3D Printing for GI Drug Delivery

Fineline Cube Jul 14, 2022

China-based Triastek Inc., a pharmaceutical 3D printing specialist, announced a partnership with US firm Eli...

Company Drug

Zhejiang Medicine’s ARX305 ADC Receives Clinical Trial Approval for CD70-Positive Cancers

Fineline Cube Jul 13, 2022

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) announced that its subsidiary NovoCodex Biopharmaceuticals Ltd has...

Company Deals

GenScript ProBio Partners with ACT Therapeutics on CAR-T Cell Therapy Development

Fineline Cube Jul 13, 2022

GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), announced a memorandum of understanding...

Company Drug

Abbisko Therapeutics’ ABSK021 Receives BTD for Giant Cell Tumor Treatment

Fineline Cube Jul 13, 2022

Shanghai-based Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its Category 1 drug ABSK021 has...

Policy / Regulatory

NMPA Reclassifies Glucosamine Sulfate to OTC, Mandates Label Revisions

Fineline Cube Jul 13, 2022

China’s National Medical Products Administration (NMPA) announced that potassium glucosamine sulfate has been reclassified from...

Policy / Regulatory

China’s JPO Launches VBP Round for Orthopedic Spine Consumables

Fineline Cube Jul 13, 2022

China’s Joint Procurement Office (JPO) announced plans on July 11 to conduct a volume-based procurement...

Company Drug

HutchMed’s Orpathys-Tagrisso Combo Shows Promise in NSCLC at WCLC

Fineline Cube Jul 13, 2022

China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the publication of an abstract detailing the SAVANNAH...

Company Drug

Junshi Biosciences’ JS203 Bispecific Antibody Receives NMPA Green Light for NHL Study

Fineline Cube Jul 13, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA)...

Drug

Eli Lilly’s Trulicity + Insulin Combo Meets Goals in China’s AWARD-CHN3 Study

Fineline Cube Jul 13, 2022

Eli Lilly (NYSE: LLY) announced that its Phase III AWARD-CHN3 study of Trulicity (dulaglutide) combined...

Policy / Regulatory

China’s 7th VBP Round Yields 65.5% Drug Price Cuts, Foreign Firms Secure Bids

Fineline Cube Jul 13, 2022

China’s 7th national volume-based procurement (VBP) round concluded with winning bids averaging a 65.5% price...

Company Drug

CDE Grants Priority Review to Ascentage’s Olerembatinib and Roche’s Crovalimab

Fineline Cube Jul 12, 2022

The Center for Drug Evaluation (CDE) has granted priority review status to two drugs: Suzhou...

Company Deals

Athenex Sells China Subsidiaries to TiHe Capital for USD 19 Million

Fineline Cube Jul 12, 2022

US-based Athenex Inc. (Nasdaq: ATNX) announced an agreement to sell all equity interests in its...

Company Deals

Tasly Pharmaceuticals and Mauna Kea Form JV to Commercialize Cellvizio in China

Fineline Cube Jul 12, 2022

China-based Tasly Pharmaceuticals (SHA: 600535) announced a joint venture (JV) with France’s Mauna Kea Technologies...

Company Medical Device

MicroPort MedBot’s Honghu Robot Wins FDA 510(k) Certification for Joint Replacement

Fineline Cube Jul 12, 2022

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that its in-house developed orthopedic surgery...

Company Medical Device

Venus Medtech’s Transcatheter Prosthetic Pulmonary Valve Approved by NMPA

Fineline Cube Jul 12, 2022

The National Medical Products Administration (NMPA) has approved Venus Medtech (Hangzhou) Inc’s (HKG: 2500) transcatheter...

Company Drug

Hengrui Medicine’s SHR-1701 + Ameile Combo Greenlit for EGFR-Mutated NSCLC Trial

Fineline Cube Jul 12, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that the National Medical Products Administration...

Posts pagination

1 … 580 581 582 … 596

Recent updates

  • Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing
  • D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally
  • Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal
  • Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer
  • Innovent Doses First Patient in Phase 1 Trial of IBI3011, China’s First Anti‑IL‑1RAP Antibody for Gout Flares
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing

Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Company Deals

Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal

Company Drug

Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.